Vatera Healthcare Partners

Vatera Healthcare Partners is a private equity and venture capital firm based in New York, specializing in investments within the healthcare sector. Founded in 2007, the firm targets companies involved in life sciences, healthcare services, biopharmaceuticals, and related product sectors. With a focus on fostering innovation and growth in the healthcare industry, Vatera Healthcare Partners seeks to identify and support companies that are positioned to make significant contributions to the sector.

Sundar Kodiyalam

Founder and Managing Director

Thomas Koestler Ph.D

Executive Director

10 past transactions

ImmusanT

Series C in 2017
ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Melinta Therapeutics

Post in 2015
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

ImmusanT

Series B in 2014
ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Melinta Therapeutics

Post in 2014
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Pearl Therapeutics

Venture Round in 2013
Pearl Therapeutics is a private company focused on developing advanced inhaled therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, asthma, and rhinosinusitis. The company specializes in creating unique dual and triple combination products that aim to improve the safety and efficacy of existing respiratory treatments. Led by a team of experts in respiratory product development, Pearl Therapeutics seeks to provide patients and healthcare providers with effective alternatives that enhance clinical outcomes. By utilizing familiar metered dose inhalers, Pearl endeavors to make its innovative therapies accessible to a broad patient population.

Melinta Therapeutics

Post in 2012
Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Pearl Therapeutics

Series D in 2012
Pearl Therapeutics is a private company focused on developing advanced inhaled therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, asthma, and rhinosinusitis. The company specializes in creating unique dual and triple combination products that aim to improve the safety and efficacy of existing respiratory treatments. Led by a team of experts in respiratory product development, Pearl Therapeutics seeks to provide patients and healthcare providers with effective alternatives that enhance clinical outcomes. By utilizing familiar metered dose inhalers, Pearl endeavors to make its innovative therapies accessible to a broad patient population.

Pearl Therapeutics

Private Equity Round in 2012
Pearl Therapeutics is a private company focused on developing advanced inhaled therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, asthma, and rhinosinusitis. The company specializes in creating unique dual and triple combination products that aim to improve the safety and efficacy of existing respiratory treatments. Led by a team of experts in respiratory product development, Pearl Therapeutics seeks to provide patients and healthcare providers with effective alternatives that enhance clinical outcomes. By utilizing familiar metered dose inhalers, Pearl endeavors to make its innovative therapies accessible to a broad patient population.

ImmusanT

Series A in 2011
ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

Pearl Therapeutics

Series C in 2010
Pearl Therapeutics is a private company focused on developing advanced inhaled therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, asthma, and rhinosinusitis. The company specializes in creating unique dual and triple combination products that aim to improve the safety and efficacy of existing respiratory treatments. Led by a team of experts in respiratory product development, Pearl Therapeutics seeks to provide patients and healthcare providers with effective alternatives that enhance clinical outcomes. By utilizing familiar metered dose inhalers, Pearl endeavors to make its innovative therapies accessible to a broad patient population.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.